China & Eli Lilly and Company
13 shared events · Importance 3 · Last updated Aug 24, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
China: China's obesity epidemic and regulatory environment shape the market. The government projects rising obesity rates and restricts direct drug advertising.
Eli Lilly and Company: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Aug 24, 2026 · 6 articles
Business
China: China is the market where mazdutide is being commercialized, representing a high-growth opportunity that underpins the royalty stream and the financing.
Eli Lilly and Company: Eli Lilly is the licensor of mazdutide to OPKO, and the royalties from this license secure the notes. The deal highlights the commercial potential of mazdutide in China.
Aug 13, 2026 · 6 articles
Business
China: China>>>'s stock market, represented by the Shanghai Stock Exchange Composite Index>>>, shed points.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.
May 20, 2026 · 72 articles
Domestic
China: Donald Trump acknowledged that his tariffs against China had previously hurt American farmers, who lost out on soybean sales, indicating potential for renewed trade tensions.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
China: AI startups like DeepSeek and Moonshot increase competition; markets impacted.
Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Apr 20, 2026 · 344 articles
International
China: China is mentioned as a potential acceptable third party to take possession of Iran's enriched uranium, due to its close relations with Tehran.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 27, 2026 · 101 articles
International
China: China is reportedly assisting Iran in restarting the production of critical weapons systems.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 18, 2026 · 309 articles
Business
China: China is another market where Leqembi is approved; the India launch does not directly affect its market.
Eli Lilly and Company: Eli Lilly faces increased competition in India's Alzheimer's market as Eisai launches Leqembi, potentially impacting its Lormalzi uptake.
Aug 03, 2026 · 6 articles
International
China: China is a major oil importer and has called for restoring normal passage. It has influence over Iran but is not directly involved.
Eli Lilly and Company: Eli Lilly and Company raised its forecast, boosting healthcare stocks. It is not connected to the event.
Mar 09, 2018 · 316 articles
Domestic
Eli Lilly and Company: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how China and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard